📊 ACH Key Takeaways
Is Accendra Health Inc./VA/ (ACH) a Good Investment?
Accendra Health is in acute financial distress with negative stockholders equity (-$464.8M), negative operating cash flow (-$170M), and negative free cash flow (-$211.6M), indicating the balance sheet is technically insolvent. Despite strong gross margins (83.8%), weak operating execution and inability to cover debt service (0.2x interest coverage) make this a financially unsustainable business model.
Fundamentals indicate severe financial stress: the business is barely profitable at the operating level, but large below-the-line losses drive a deeply negative net margin and materially weaken the balance sheet. Liquidity is tight, leverage is heavy, and cash flow is substantially negative, so modest revenue growth does not currently translate into durable earnings quality or financial stability.
Accendra Health Inc./VA/ Key Strengths (ACH)
- Strong gross margin of 83.8% indicates pricing power in medical distribution
- Cash balance of $336.9M provides near-term operational runway
- Operates in stable healthcare wholesale sector with recurring revenue characteristics
- Revenue is still growing modestly year over year, indicating underlying demand has not collapsed
- Gross margin of 19.0% suggests the core distribution business retains some gross profit generation capacity
- Cash balance of $281.99M provides limited near-term liquidity support despite overall stress
ACH Stock Risks: Accendra Health Inc./VA/ Investment Risks
- Negative stockholders equity of -$464.8M indicates technical balance sheet insolvency
- Operating cash flow of -$170M with free cash flow of -$211.6M reveals unsustainable cash burn destroying equity value
- Interest coverage ratio of 0.2x means operating income cannot service $1.5B debt obligations
- Current ratio of 0.49x indicates severe liquidity stress and probable debt covenant violations
- Unprofitable operations (-$6.5M net income) with operating margin collapse to 2.7% despite high gross margins suggest structural operating problems
- Net loss of $1.10B and net margin of -39.8% indicate extremely weak earnings quality and major non-operating or impairment-related pressure
- Negative stockholders equity, current ratio of 0.58x, and interest coverage of 0.3x point to elevated solvency and refinancing risk
- Negative operating cash flow and free cash flow show the business is not self-funding and may require asset sales, restructuring, or external capital
Key Metrics to Watch
- Operating cash flow trajectory and monthly burn rate
- Cash balance depletion timeline and covenant compliance status
- Operating expense reduction initiatives and path to operating profitability
- Debt restructuring negotiations or covenant amendment status
- Operating cash flow and free cash flow trend
- Interest coverage and current ratio
Accendra Health Inc./VA/ (ACH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ACH Profit Margin, ROE & Profitability Analysis
ACH vs Healthcare Sector: How Accendra Health Inc./VA/ Compares
How Accendra Health Inc./VA/ compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Accendra Health Inc./VA/ Stock Overvalued? ACH Valuation Analysis 2026
Based on fundamental analysis, Accendra Health Inc./VA/ has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Accendra Health Inc./VA/ Balance Sheet: ACH Debt, Cash & Liquidity
ACH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Accendra Health Inc./VA/'s revenue has declined by 72% over the 5-year period, indicating business contraction. The most recent EPS of $-0.53 indicates the company is currently unprofitable.
ACH Revenue Growth, EPS Growth & YoY Performance
ACH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $627.8M | -$6.5M | $-0.08 |
| Q3 2025 | $686.8M | -$12.8M | $-0.16 |
| Q2 2025 | $660.4M | -$21.9M | $-0.42 |
| Q1 2025 | $2.6B | -$21.9M | $-0.29 |
| Q3 2024 | $2.6B | -$6.4M | $-0.08 |
| Q2 2024 | $2.6B | -$21.9M | $-0.37 |
| Q1 2024 | $2.5B | -$21.9M | $-0.29 |
| Q3 2023 | $2.5B | -$6.4M | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Accendra Health Inc./VA/ Dividends, Buybacks & Capital Allocation
ACH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Accendra Health Inc./VA/ (CIK: 0000075252)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACH
What is the AI rating for ACH?
Accendra Health Inc./VA/ (ACH) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 95% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACH's key strengths?
Claude: Strong gross margin of 83.8% indicates pricing power in medical distribution. Cash balance of $336.9M provides near-term operational runway. ChatGPT: Revenue is still growing modestly year over year, indicating underlying demand has not collapsed. Gross margin of 19.0% suggests the core distribution business retains some gross profit generation capacity.
What are the risks of investing in ACH?
Claude: Negative stockholders equity of -$464.8M indicates technical balance sheet insolvency. Operating cash flow of -$170M with free cash flow of -$211.6M reveals unsustainable cash burn destroying equity value. ChatGPT: Net loss of $1.10B and net margin of -39.8% indicate extremely weak earnings quality and major non-operating or impairment-related pressure. Negative stockholders equity, current ratio of 0.58x, and interest coverage of 0.3x point to elevated solvency and refinancing risk.
What is ACH's revenue and growth?
Accendra Health Inc./VA/ reported revenue of $627.8M.
Does ACH pay dividends?
Accendra Health Inc./VA/ does not currently pay dividends.
Where can I find ACH SEC filings?
Official SEC filings for Accendra Health Inc./VA/ (CIK: 0000075252) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACH's EPS?
Accendra Health Inc./VA/ has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ACH's fundamental grade?
Based on our AI fundamental analysis in June 2026, Accendra Health Inc./VA/ has a D grade with 95% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ACH stock overvalued or undervalued?
Valuation metrics for ACH: ROE of N/A (sector avg: 15%), net margin of -1.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ACH's AI grade for 2026?
Our dual AI analysis gives Accendra Health Inc./VA/ a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACH's free cash flow?
Accendra Health Inc./VA/'s operating cash flow is $-170.0M, with capital expenditures of $41.6M. FCF margin is -33.7%.
How does ACH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.49 (avg: 2).